President at NABR
President of NABR quoted discussing that NAMs must be validated before replacing animal models and noting limitations of AI in drug development.
How media typically covers Matthew R. Bailey
Directly quoted in these articles
The FDA announced a plan to phase out animal model requirements in drug development by promoting validated alternative methodologies including organ-on-chip systems, in vitro assays, and AI-based computational models for monoclonal antibodies and other drug candidates.
“President of NABR quoted discussing that NAMs must be validated before replacing animal models and noting limitations of AI in drug development.”